FOLD stock forecast
Our latest prediction for Amicus Therapeutics, Inc.'s stock price was made on the Jan. 15, 2020 when the stock price was at 10.39$.
In the short term (2weeks), FOLD's stock price should underperform the market by -2.54%. During that period the price should oscillate between -9.50% and +8.96%.
In the medium term (3months), FOLD's stock price should underperform the market by -10.67%. During that period the price should oscillate between -39.57% and +18.73%.Get email alerts
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
At the moment the company generates 160M USD in revenues.
On its last earning announcement, the company reported a loss of -1.54$ per share.
The book value per share is 2.97$
Three months stock forecastJan. 15, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|